CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Testosterone gel (FE 99903)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01370369
NCT01370369Phase 2Completed
CompareCT.gov

A Phase 2 Open-Label, Sequential Dose Escalation Study to Evaluate the Efficacy, Pharmacokinetics and Safety of Three Volumes (1.25, 2.50 and 3.75 mL) of Testosterone Gel 2% (FE 999303) Equivalent to 23, 46 And 70 mg of Testosterone in Hypogonadal Males

Ferring Pharmaceuticals·interventional·Posted Jun 9, 2011·Updated Sep 13, 2017

In Brief

A Phase 2 clinical trial evaluating Testosterone gel (FE 99903) for Testicular Hypogonadism. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This is an open-label study of a single and repeated application of three dose levels of topical testosterone in hypogonadal males with morning serum testosterone concentrations \< 297 ng/dL.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTesticular Hypogonadism
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJun 9, 2011
Enrollment StartMay 1, 2011
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 15.1 years ago

Interventions

Testosterone gel (FE 99903)drug